India Pharma Outlook Team | Tuesday, 31 March 2026
Wockhardt has moved closer to market approval after its antibiotic Zaynich received a positive nod from the Central Drugs Standard Control Organization, marking a breakthrough in antibiotic space.
The development highlights a Breakthrough in antibiotic space as the drug targets rising drug-resistant infections and clears a key regulatory step toward approval.
Zaynich, a combination of Zidebactam and Cefepime, has been in development for over 15 years. Built by a team of more than 150 scientists, the drug uses a novel β-lactam enhancer-based mechanism designed to fight highly resistant Gram-negative pathogens, including MDR and XDR strains that are rising globally.
Also Read: Consumer Trust in OTC Products: The Science Behind Safety
The SEC’s recommendation follows a detailed review of clinical data, including nine Phase 1 studies, a Phase 2 trial targeting meropenem-resistant infections, and a global Phase 3 study. In that Phase 3 trial involving more than 500 patients, Zaynich delivered stronger clinical and microbiological outcomes compared to meropenem.
The Wockhardt Zaynich approval case is further supported by strong results in India, where earlier studies showed over 97% clinical efficacy in treating serious infections such as hospital-acquired pneumonia, bloodstream infections, and intra-abdominal infections. In addition, 85 compassionate-use cases across India, the US, Malaysia, and France showed promising outcomes where treatment options were limited.
Regulatory filings are already under review in the US and EU. With growing concern around antibiotic resistance, Zaynich positions Wockhardt at the forefront of global efforts to develop effective therapies for critical infections.
.jpg)
.jpg)
